Muscular Dystrophy News Today covered the press release for cTAP’s recent publication “Functional trajectories before and after loss of ambulation in Duchenne muscular dystrophy and implications for clinical trials.” Muscular Dystrophy News Today is daily digital news journal that seeks to give MD patients and their support systems access to the latest science and research news pertaining to the disease. View Full Article The publication was also covered on The American Journal of Managed Care...

Jul 24, 2024 - Study co-funded by cTAP and CureDuchenne highlights the need for more specific enrollment criteria that could increase patient participation and drive more comprehensive therapeutic evaluation. Read the full press release on PR Newswire Read the full scientific article in PLoS ONE

CAMBRIDGE, Mass., February 7, 2023 - The Collaborative Trajectory Analysis Project (cTAP), a global coalition in rare disease, has announced evidence to support patient-centric alternatives to the conventional use of genetically matched placebo controls in clinical trials for RNA-editing therapies in Duchenne Muscular Dystrophy (DMD). Published in Neurology, the large, multi-institution, multi-national study of more than 700 patients with DMD quantified the impact of genotype classes on observed disease. Results showed that less than 2...

cTAP founders Susan J. Ward and James Signorovitch have written an article featured in Genetic Engineering & Biotechnology News: The Problem with Clinical Trials in Duchenne—and What We Can Do About It. View the Full Article

Results published in peer-reviewed journal Neurology indicate that real-world data (RWD) and natural history data (NHD) could augment or replace placebo controls in DMD clinical trials. Use of RHD and NHD have potential to streamline and accelerate clinical programs targeting new treatments for DMD. CAMBRIDGE, Mass., September 8, 2020 /PRNewswire/ – The Collaborative Trajectory Analysis Project (cTAP), a multi-stakeholder, global research coalition in Duchenne muscular dystrophy (DMD), today announced results from the largest ever multi-national,…

cTAP has been included in an article featured in Nature Biotechnology: Their Lives in Their Hands. View the Full PDF

The collaborative Trajectory Analysis Project (cTAP), a multi-stakeholder, global coalition in Duchenne muscular dystrophy (DMD), has published research in the journal PLOS ONE providing quantitative insights to assist the design and analysis of clinical trials in patients with DMD. READ FULL PRESS RELEASE ON BUSINESSWIRE: cTAP Publishes Comprehensive Analysis of the North Star Ambulatory Assessment (NSAA), a Newly Adopted Primary Outcome Measure in Clinical Trials of Patients with Duchenne Muscular Dystrophy

Published December 5, 2018 The collaborative Trajectory Analysis Project (cTAP), a multi-stakeholder, non-competitive global coalition in Duchenne muscular dystrophy, today announced that Analysis Group Managing Principal James Signorovitch, cTAP’s partner, has been selected as recipient of ISPOR’s “Best General Research Podium Presentation” award at ISPOR Europe 2018, which recently took place in Barcelona, Spain. Dr. Signorovitch’s research presentation titled Ambulatory Function in Duchenne Muscular Dystrophy (DMD): The Characteristic Trajectory and Variation Across Individuals, will be...

cTAP has been included in the new book, Moneyball Medicine: Thriving in the New Data-Driven Healthcare Market (pg. 81-82). View the Full PDF

Published October 1, 2018 The collaborative Trajectory Analysis Project (cTAP), a multi-stakeholder, non-competitive global coalition in Duchenne muscular dystrophy, today announced the acceptance of a late-breaking abstract for presentation at the 23rd International Congress of the World Muscle Society. This is in addition to the two previously accepted submissions that cTAP collaborators will present at the Congress, which is being held October 2-6, 2018 at the Intercontinental Hotel in Mendoza, Argentina. READ FULL ARTICLE: cTAP...